Market Access Impact: Non-Small Cell Lung Cancer (US) 2016
7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them?
In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s driving the top 3 brands’ small share gains? Which barrier has the biggest impact, and which two brands is it hurting the most? Would eliminating market barriers close the gaps between leading brands and lower-ranked rivals?
Find out in Market Access Impact: NSCLC. Request sample pages
The report covers 10 major NSCLC drugs from AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck & Co., Novartis, Pfizer/EMD Serono, and Roche. You’ll learn which brands take the biggest hit from 7 different market barriers, which barriers cost your brand the most share, and which competitors you’re losing share to and taking it from.
Not your market? Click here to see the EU5 report
Top Takeaways
Market Access Impact: NSCLC explores key issues affecting NSCLC drug manufacturers. You’ll learn:
How barriers affect market access:
We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s driving the top 3 brands’ small share gains? Which barrier has the biggest impact, and which two brands is it hurting the most? Would eliminating market barriers close the gaps between leading brands and lower-ranked rivals?
Find out in Market Access Impact: NSCLC. Request sample pages
The report covers 10 major NSCLC drugs from AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck & Co., Novartis, Pfizer/EMD Serono, and Roche. You’ll learn which brands take the biggest hit from 7 different market barriers, which barriers cost your brand the most share, and which competitors you’re losing share to and taking it from.
Not your market? Click here to see the EU5 report
Top Takeaways
- Three brands lead the pack: While more than half of the doctors surveyed prescribe eight of the ten brands covered in the report, nearly all doctors prescribe the top three brands.
- Most brands are losing share: Only the three most prescribed brands see net market share gains because of market barriers. The rest see small losses.
- “Other” brands benefit the most: They take share from all but one of the surveyed brands, and in aggregate, their total net share gain is larger than that of any surveyed brand.
- The top barrier affects two brands disproportionately: Significantly more doctors experience this barrier with the most prescribed, and fourth most prescribed brands.
- Market access affects more prescriptions than other barriers: Taken together barriers related to market access affect slightly more prescriptions than any other barrier.
- One brand has a small perception problem: 15% of the doctors surveyed would not consider prescribing this brand. For the rest of the surveyed brands, that number is below 10%.
- Avastin (bevacizumab; Roche)
- Cyramza (ramucirumab; Eli Lilly)
- Gilotrif (afatinib; Boehringer Ingelheim)
- Iressa (gefitinib; AstraZeneca)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; BMS)
- Portrazza (necitumumab; Eli Lily)
- Tarceva (erlotinib; Roche)
- Xalkori (crizotinib; Pfizer/EMD Serono)
- Zykadia (ceritinib; Novartis)
Market Access Impact: NSCLC explores key issues affecting NSCLC drug manufacturers. You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? %li%What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with NSCLC in total in the last month
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1.WHAT ARE MARKET BARRIERS?
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
